abstract |
The invention relates to glycoprotein VI (GPVI), its isolation, purification and methods for recombinant production. In particular, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events directly or indirectly correlated with blood clotting disorders such as thrombotic and cardiovascular disorders. Recombinant extracellular protein can also be used to establish screening assays to find potential membrane-bound GPVI inhibitors to inhibit thrombocyte and platelet collagen binding, respectively. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases. |